VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- Canadian Blood Services is proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients infected with the virus. Today, the national blood authority and operator collected its first COVID-19 convalescent plasma donation in Vancouver.
Im delighted to be able to help out a really good cause. I have been an active blood donor for 15 years. Im pleased my unfortunate situation can help somebody else. I think Im doing a little bit of good out of all this. says Jerry Glubisz, Canadian Blood Services first COVID-19 convalescent plasma donor.
Canadian Blood Services is establishing a national convalescent plasma collection program. The blood operator is now recruiting potential convalescent plasma donors across the country through its new online registry.
Convalescent plasma may help patients recover from COVID-19, but this has not yet been proven. Well-designed clinical trials, like CONCOR, will help provide the necessary information about whether this is a safe and effective treatment option for patients, says Dr. Dana Devine, chief scientist with Canadian Blood Services. Were making an important contribution to research on a global scale that could help patients in Canada and around the world.
Over the next few weeks more convalescent plasma donors, like Jerry Glubisz, may donate at one of 11 Canadian Blood Services donor centres that have the capability to collect blood components, like plasma, through a process called apheresis. These donor centres are located in Vancouver, Calgary, Edmonton, Saskatoon, Regina, Winnipeg, London, Hamilton, Toronto, Ottawa and Halifax.
Initially, all convalescent plasma donations will be supplied to Canadian physicians caring for patients with COVID-19 in the context of the CONCOR trial and under the authorization of Health Canada.
Including both of Canadas public blood operators (Canadian Blood Services and Hma-Qubec), there are 10 research teams and more than 50 hospitals across the country currently participating in CONCOR. Patient involvement in the clinical trial will be determined by their treating physician at a participating hospital in consultation with the patient and/or the patients family. Patients with COVID-19 who are looking for more information on convalescent plasma as a treatment option are encouraged to visit CONCOR1.ca.
While Canadian Blood Services has officially started collecting convalescent plasma, these donations must still undergo all necessary testing and processing before being issued for use by physicians, as per blood safety and quality standards. Transfusions of convalescent plasma are expected to begin within a few weeks when the trial begins.
A convalescent plasma donation is the same as a plasma donation; however, a specific donor is needed for this clinical trial. In addition to meeting Canadas current plasma donor eligibility criteria, convalescent plasma donors must be younger than 67 years of age, previously confirmed positive for COVID-19 by a laboratory test, and fully recovered from the virus and symptom free for at least 28 days to participate. Donors must also live within driving distance of a donor centre located in one of the aforementioned cities. Anyone who meets these requirements is encouraged to join Canadian Blood Services online registry. Additional testing will be done at the time of collection to ensure there are adequate antibodies against the COVID-19 virus in the donors plasma to be part of the trial.
Registered convalescent plasma donors who may be eligible are being contacted now and all convalescent plasma donation appointments are being booked as donors are qualified to participate by Canadian Blood Services Centre for Innovation which oversees research and development for the organization.
Canadian Blood Services is not accepting walk-in donors for any of its collection programs during the pandemic.
Media assets
As per current physical distancing measures, media are not permitted to visit Canadian Blood Services donor centres. To ensure media have access to assets necessary to provide coverage, raw footage and an uncut interview with Canadian Blood Services first convalescent plasma donor will be made available.
Web-based interviews with Mr. Glubisz and with convalescent plasma donors in other areas of Canada may also be arranged through Canadian Blood Services.
Please contact media@blood.ca for more information.
About Canadian Blood Services
Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma and stem cells, we provide services for patients on behalf of all provincial and territorial governments except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians.
About Canadian Blood Services Research Activities
Canadian Blood Services, through its Centre for Innovation, conducts and supports research projects in key priority areas that span the translational continuum from bench to bed side. The focus is on transfusion science and medicine but also related fields such as cellular therapies (in particular hematopoietic stem cell transplantations) and organ and tissue transplantation. Our research findings are published in peer-reviewed journals or directly shared with stakeholders.
Instrumental to our research efforts are discovery and applied research laboratories led by university-affiliated Canadian Blood Services staff scientists, as well as our medical experts and adjunct scientists. Complementing these core research teams, the Centre for Innovation facilitates a national and international research network of blood system experts through competitive research funding opportunities, collaborations and contract research.
/CanadasLifeline@CanadasLifeline1 888 2DONATE
FOR MORE INFORMATIONTEL. 1-877-709-7773EMAILmedia@blood.ca
Continue reading here:
- First of its kind stem cell transplant treatment in Boston restores vision to patient - Yahoo - April 8th, 2025
- People are getting costly stem cell injections for knee osteoarthritis, but we don't know if they work - Medical Xpress - April 6th, 2025
- Say goodbye to joint pain without surgery: Expert shares 8 tips on diet plan, lifestyle tweaks, treatments and therapies - Hindustan Times - April 6th, 2025
- Breaking Barriers in Autism: European Wellness Biomedical Group Unveils Bioregenerative Breakthroughs with Prof. Mike Chan -... - April 6th, 2025
- Revolutionizing Success in the Cell Therapy Regenerative - openPR.com - April 4th, 2025
- 5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io - April 4th, 2025
- Boys with cancer can face infertility as adults. Can storing their stem cells help? - Ravalli Republic - April 4th, 2025
- Tip Sheet: Nutrition for People Receiving Stem Cell Transplants, Art Therapy for Cancer Patients, Treating a Rare Type of Colon Cancer and Graduate... - April 4th, 2025
- Human Organoid Market is Set to Revolutionize Drug Discovery and Disease Modeling - openPR.com - April 1st, 2025
- Doctors Told Him He Was Going to Die. Then A.I. Saved His Life. - The New York Times - March 24th, 2025
- Japan team says stem cell treatment helped improve spinal cord injuries | NHK WORLD-JAPAN News - NHK WORLD - March 22nd, 2025
- Boost in cancer treatment: PGI working on lab for stem cell, gene therapies - The Times of India - March 19th, 2025
- Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom - openPR - March 19th, 2025
- Neuroregeneration Therapy Market Forecasted to Expand at 5.3% CAGR, Reaching USD 64.8 Billion by 2034 - Transparency Market Research, Inc -... - March 19th, 2025
- Cell Therapy Market Surges as Breakthrough Innovations Transform Regenerative Medicine - openPR - March 17th, 2025
- Infinite Health Integrative Medicine Center Fights Chronic Pain with Stem Cell Prolotherapy - PR Newswire - March 14th, 2025
- Stem Cell and Exosome Innovations at Infinite Health Integrative Medicine Center Offers New Hope for Parkinson's Disease - PR Newswire - March 14th, 2025
- Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion - TradingView - March 14th, 2025
- Cell Therapy Market Poised for Exponential Growth, Projected to Reach USD 44.6 Billion by 2034 - openPR - March 14th, 2025
- Trial Repairs Irreversible Corneal Damage With Stem Cell Therapy - Anti Aging News - March 11th, 2025
- Advancing Regenerative Medicine: A Comprehensive Outlook on the Global Cell Therapy Market - openPR - March 7th, 2025
- Top 3 Grants in Regenerative Medicine: February 2025 - RegMedNet - March 7th, 2025
- The future of cell therapy: scaling production for global reach - Drug Target Review - March 7th, 2025
- Stem Cell Therapy Repairs Corneal Damage in Trial - Mirage News - March 7th, 2025
- Autologous Cell Therapy Market Anticipated to Hit USD 12.1 Billion by 2031: Persistence Market Research Study - openPR - March 7th, 2025
- Regenerative Therapies Market Forecast to Reach USD 24.41 Billion by 2033 - Persistence Market Research - openPR - March 5th, 2025
- This Japanese Regenerative Medicine Company Just Secured Its Path to NASDAQ Through a $242M Deal - StockTitan - March 5th, 2025
- Ryoncil, the first FDA-approved mesenchymal stromal cell therapy - Yahoo - March 5th, 2025
- Animal Stem Cell Therapy Market Forecast to Reach USD 437.3 - openPR - March 3rd, 2025
- A Navy SEALs Journey to Stem Cell Treatment: The Future of Medicine is Here, Just Not in America - SOFREP - March 3rd, 2025
- InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug - Forbes - March 3rd, 2025
- VUMC Part of New Study Validating Curative Therapy for Sickle Cell Disease A - Wgnsradio - March 1st, 2025
- Advancing Stem Cell Therapy and Equity in Patient Care - Targeted Oncology - February 27th, 2025
- How Stem Cell Treatment Reversed A Pro Athlete's Life-threatening Long COVID Disease When all Other treatment Failed - Medical Tourism Magazine - February 27th, 2025
- Allogeneic Cell Therapy Market Size to Hit USD 4,677.38 Million by 203 - BioSpace - February 27th, 2025
- Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologics - Pharmaceutical Executive - February 27th, 2025
- Mount Sinai-Led Research Team Identifies Underlying Mechanisms of Age-Related Dysfunction in Glands Crucial to Eye Function | Newswise - Newswise - February 25th, 2025
- Experts explore the future of iPSC-based cell therapies - Drug Target Review - February 19th, 2025
- Longeveron Announces World Health Organization Approval of laromestrocel as International Non-proprietary Name for Stem Cell Therapy Lomecel-B -... - February 19th, 2025
- The impact of cytokines on stem cells and organoid research in drug discovery - News-Medical.Net - February 19th, 2025
- Revolutionary FDA-Approved Stem Cell Partnership Puts Adia Med at Forefront of Regenerative Medicine - StockTitan - February 19th, 2025
- Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - BioSpace - February 19th, 2025
- Bahrain's pioneering use of sickle cell disease treatment hailed by medical experts - The National - February 19th, 2025
- Uganda Treats First Patient Using Stem Cell Therapy - AllAfrica - Top Africa News - February 19th, 2025
- Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - StreetInsider.com - February 17th, 2025
- Diversity of Cells Allow Colon Cancer to Resist Treatment and To Metastasize - MedicalResearch.com - February 15th, 2025
- Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm - Nature.com - February 13th, 2025
- Experimental cell therapy trial treats first Sjgrens disease patient - University of Wisconsin School of Medicine and Public Health - February 11th, 2025
- Stem Cell Therapy Market Types, Applications, Share, Growth - openPR - February 6th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 6th, 2025
- Revitalizing Health with Stem Cell Therapy: A Groundbreaking Path To Longevity and Wellness - openPR - February 4th, 2025
- Gene therapy offers new hope for sickle cell disease patients - Open Access Government - February 4th, 2025
- Scientists trial implant to patch up the heart - BBC.com - February 2nd, 2025
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
Recent Comments